

VPA10509/005/001

Espacox 50 mg/ml oral suspension for pigs

Variation	Summary	Date
Vet - C6	VNRA - Vet - C6 - - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex	17/08/26
Vet - C1	VNRA - Vet - C1 - - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	17/08/26
Vet - A4	VNRA - Vet - A4 - - Vet - A4 Administrative changes - Change in ATCvet Code	23/07/25
Vet - G.I.18	VRA-S - Vet - G.I.18 - - Vet - G.I.18 - One-off alignment of the product information with version 9.0* of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products authorised in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	23/07/25
Vet - F.I.f.1	VRA-S - Vet - F.I.f.1 - 1. Substantial changes in the updated version of the ASMF or the active substance part of the dossier - F.I.f.1 Quality Changes - Active Substance - Other changes to the active substance - Substantial changes in the updated version of the ASMF or the active substance part of the dossier	28/11/22
Vet - B21	VNRA - Vet - B21 - Replacement or addition of a secondary packaging site of a finished product - B21 Changes to the quality part of the dossier: Replacement or addition of a secondary packaging site of a finished product	19/10/22
B.II.b.3.f	IB - B.II.b.3.f - f) Minor change in the manufacturing process of an aqueous oral suspension - B.II.b.3.f - QUALITY CHANGES - FINISHED PRODUCT - Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Minor change in the manufacturing process of an aqueous oral suspension	09/03/22